Surinder K. Sharma

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Fiona Thistlethwaite, David E. Gilham, Ryan D. Guest et al. · Cancer Immunology Immunotherapy · 2017 · 395 citations · Full text

Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds

Caroline J. Springer, Kenneth D. Bagshawe, Surinder K. Sharma et al. · European Journal of Cancer and Clinical Oncology · 1991 · 116 citations

Novel Compounds, Drug Targeting, Nude Mice +9

A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug

Astrid Mayer, Roslyn J. Francis, Surinder K. Sharma et al. · Clinical Cancer Research · 2006 · 80 citations

Nanotherapeutics, Prodrug Activation, Immunology +19

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

Janet Martin, Stephen M. Stribbling, Grace K. Poon et al. · Cancer Chemotherapy and Pharmacology · 1997 · 79 citations

Plasma Levels, Medicine, Immunology +5

Synthesis of bimetallic Pt–Cu nanoparticles and their application in the reduction of rhodamine B

Henam Premananda Singh, Nikesh Gupta, Surinder K. Sharma et al. · Colloids and Surfaces A Physicochemical and Engineering Aspects · 2012 · 79 citations

Materials Science, Chemical Engineering, Rhodamine B +8